Frontier Biotechnologies

Frontier Biotechnologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Frontier Biotechnologies (688221.SS) as of Oct 16, 2026 is 95.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 94.90 % — a change of 0.81% (higher).

FCF Conversion

95.67 %

YoY

0.81%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Frontier Biotechnologies is 2025 95.67 % . FCF Conversion Rate (FCF/EBITDA) of Frontier Biotechnologies was 2024 94.90 % . It decreases by 0.81% higher compared to the previous year.

The Frontier Biotechnologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
47.19 CNY
Jan 1, 2019
65.58 CNY
Jan 1, 2020
154.55 CNY
Jan 1, 2021
219.27 CNY
Jan 1, 2022
120.36 CNY
Jan 1, 2023
120.54 CNY
Jan 1, 2024
94.90 CNY
Jan 1, 2025
95.67 CNY
The Frontier Biotechnologies FCF Conversion history
YEARFCF ConversionYoY
95.67 %+0.81%
94.90 %-21.27%
120.54 %+0.14%
120.36 %-45.11%
219.27 %+41.88%
154.55 %+135.65%
65.58 %+38.99%
47.19 %-71.15%
163.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Frontier Biotechnologies Stock analysis

What does Frontier Biotechnologies do? Frontier Biotechnologies Inc is a biotechnology company headquartered in Nanjing, China. It focuses on research, development, production, and sale of medicines. The company has 495 employees and completed its IPO on October 28, 2020. Its products include Aikening and a combination regimen of Albuvirtide (ABT) plus 3BNC117 for HIV treatment, currently in clinical stages. Another clinical-stage product is the transdermal analgesic patch AB001 for muscle, skeleton, and joint pain. The company operates in both domestic and overseas markets. Frontier Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier Biotechnologies stock

FCF Conversion Rate (FCF/EBITDA) of Frontier Biotechnologies is 95.67 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Frontier Biotechnologies changed from 94.90 % to 95.67 %, representing a 0.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Frontier Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Frontier Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Frontier Biotechnologies

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Frontier Biotechnologies